Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533759

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1533759

Chronic Renal Failure Therapeutics

PUBLISHED:
PAGES: 178 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5600
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 16800

Add to Cart

Description

Table of Contents

Global Chronic Renal Failure Therapeutics Market to Reach US$22.9 Billion by 2030

The global market for Chronic Renal Failure Therapeutics estimated at US$20.1 Billion in the year 2023, is expected to reach US$22.9 Billion by 2030, growing at a CAGR of 1.9% over the analysis period 2023-2030. Antihypertensive Drugs, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$16.3 Billion by the end of the analysis period. Growth in the Antianemia Drugs segment is estimated at 2.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.5 Billion While China is Forecast to Grow at 4.0% CAGR

The Chronic Renal Failure Therapeutics market in the U.S. is estimated at US$5.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 4.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.4% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.9% CAGR.

Global Chronic Renal Failure Therapeutics Market - Key Trends and Drivers Summarized

Chronic renal failure, also known as chronic kidney disease (CKD), is a progressive condition characterized by the gradual loss of kidney function over time. This debilitating disease affects millions worldwide, leading to serious health complications such as cardiovascular disease, anemia, and bone disorders. The primary goal of therapeutics for CKD is to slow disease progression, manage symptoms, and improve the quality of life for patients. Early-stage treatments often include lifestyle modifications such as dietary changes, exercise, and blood pressure control. Medications like angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are commonly prescribed to control hypertension and reduce proteinuria, which helps to preserve kidney function. Additionally, diabetes management is crucial in CKD patients, as hyperglycemia can exacerbate kidney damage.

As CKD progresses to more advanced stages, therapeutic strategies become more complex and intensive. Anemia management often involves the use of erythropoiesis-stimulating agents (ESAs) and iron supplements to boost red blood cell production and alleviate fatigue. Mineral and bone disorder management is addressed through phosphate binders, vitamin D analogs, and calcimimetics to maintain mineral balance and bone health. For patients reaching end-stage renal disease (ESRD), renal replacement therapies such as dialysis and kidney transplantation become necessary. Hemodialysis and peritoneal dialysis are life-sustaining treatments that perform the filtration functions of the kidneys, while transplantation offers a potential cure but requires lifelong immunosuppression to prevent organ rejection.

The growth in the chronic renal failure therapeutics market is driven by several factors, including the increasing prevalence of CKD due to rising rates of diabetes, hypertension, and aging populations. Technological advancements in diagnostic tools have improved the early detection of CKD, enabling timely intervention and better disease management. Consumer behavior towards proactive health management and regular screenings has also contributed to the early diagnosis and treatment of CKD. Additionally, significant investments in research and development by pharmaceutical companies have led to the introduction of novel therapies and improved formulations of existing drugs. Regulatory support and favorable reimbursement policies have further facilitated the adoption of advanced CKD treatments. The expansion of healthcare infrastructure, particularly in emerging economies, has increased access to CKD therapeutics and renal replacement therapies. These factors collectively ensure a dynamic and growing market for chronic renal failure therapeutics, aiming to enhance patient outcomes and extend the lives of those affected by this chronic condition.

Select Competitors (Total 37 Featured) -

  • Akebia Therapeutics, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche AG
  • FibroGen, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Services, Inc.
  • Kissei Pharmaceutical Co., Ltd.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc
  • Sanofi SA
  • Siemens Healthineers AG;
Show more
Product Code: MCP26813

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Chronic Renal Failure Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Kidney Failure Associated With Rising Global Prevalence of Diabetes and Hypertension Spurs Demand for Renal Failure Therapeutics
    • Advances in Dialysis Technology Enhance Treatment Efficacy and Patient Comfort
    • Development of Novel Pharmacologic Treatments to Delay Kidney Disease Progression
    • Growing Focus on Preventive Healthcare Measures & Expansion of Renal Disease Awareness Programs Bolster Early Intervention Efforts & Diagnosis Rates
    • Impact of Aging Population on Healthcare Systems and Renal Therapy Needs
    • Advancements in Gene Therapy and Stem Cell Research Open New Treatment Avenues
    • Global Health Initiatives Aimed at Improving Access to Renal Care to Benefit Market Growth
    • Review of the Economic Burden of Chronic Renal Failure
    • Innovations in Kidney Transplant Procedures and Immunosuppressive Therapies
    • Shift Towards Personalized Medicine in Managing Chronic Kidney Disease
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Chronic Renal Failure Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Antihypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Antihypertensive Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Antihypertensive Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Antianemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Antianemia Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Antianemia Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • CHINA
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • INDIA
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Chronic Renal Failure Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Chronic Renal Failure Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Chronic Renal Failure Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Chronic Renal Failure Therapeutics by Drug Type - Antihypertensive Drugs, Antianemia Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Chronic Renal Failure Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Antihypertensive Drugs, Antianemia Drugs and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!